SCHEMBL6722237

SCHEMBL6722237

CC(C)Cn1c(C(C)O)nc2cnc3ccccc3c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
TSHR P16473 5/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
TLR7 Q9NYK1 3/20 0.42
LMNA P02545 3/20 0.42
POLB P06746 2/20 0.42
HRH2 P25021 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42
ADORA2A P29274 1/20 0.42
ADRA1A P35348 1/20 0.42
NUDT1 P36639 1/20 0.42
HTR2B P41595 1/20 0.42
PDE4D Q08499 1/20 0.42
KCNH2 Q12809 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
TLR8 Q9NR97 1/20 0.41
JAK1 P23458 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723854 0.88 NPSR1 (0.52) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL6723981 0.85 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1TLR7LMNAPOLB
SCHEMBL6724500 0.84 NPSR1 (0.43) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL6722356 0.84 TLR7 (0.41) SMN1; SMN2TSHRALDH1A1GAATLR7
SCHEMBL6724014 0.83 SMN1; SMN2 (0.47) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL6723871 0.83 TLR7 (0.52) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL6719567 0.83 TLR7 (0.43) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL9602807 0.82 TLR7 (0.43) SMN1; SMN2TSHRALDH1A1GAATLR7
SCHEMBL1170709 0.82 TLR7 (0.49) SMN1; SMN2TSHRALDH1A1TLR7LMNA
SCHEMBL6726678 0.82 ALDH1A1 (0.39) SMN1; SMN2TSHRALDH1A1GAATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6790961-B2 REACTING A 3-AMINO-4-(SUBSTITUTED)AMINO-2-CHLOROQUINOLINE WITH AN ALKYLCARBONYL CHLORIDE TO FORM THE 2-ALKYLCARBOXAMIDE INTERMEDIATE 3M INNOVATIVE PROPERTIES COMPANY 2004-09-14 US disclosed
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6686472-B2 Process for preparing 1-substituted, 2-substituted 1-H-imidazo(4,5-c)quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2004-02-03 US disclosed
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines 3M INNOVATIVE PROPERTIES COMPANY 2003-11-13 US disclosed
US-6608201-B2 Amidation of a 2-halo-3,4-diaminoquinoline with an acid chloride; dehalogenation, amination with ammonia; cyclization 3M INNOVATIVE PROPERTIES COMPANY 2003-08-19 US disclosed
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2003-06-26 US disclosed
EP-0872478-B1 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING & MFG (US) 2002-12-18 EP disclosed
US-6465654-B2 ANTIVIRAL AGENTS, THAT INDUCE BIOSYNTHESIS OF INTERFERON, AND INHIBIT TUMOR FORMATION 3M INNOVATIVE PROPERTIES COMPANY 2002-10-15 US disclosed
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2002-08-22 US disclosed
US-6348462-B1 VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2002-02-19 US disclosed
US-5977366-A 1-substituted, 2-substituted 1H-imidazo[4,5-c] quinolin-4-amines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-11-02 US disclosed
EP-0582581-B1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING & MFG (US) 1999-05-06 EP disclosed
EP-0872478-A2 Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-10-21 EP disclosed
US-5741909-A PHARMACEUTICAL COMPOSITIONS WHICH ACT AS ANTIVIRAL AGENTS, INDUCE BIOSYNTHESIS OF INTERFERON AND INHIBIT TUMOR FORMATION IN ANIMALS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US disclosed
US-5605899-A VIRICIDES, BIOSYNTHESIS OF INTERFERONS, ANTITUMOR AGENTS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-02-25 US disclosed
US-5389640-A Viricides, antitumor agents MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-02-14 US disclosed
EP-0582581-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO 4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-02-16 EP disclosed
WO-1992015582-A1 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212270-A1 Process for preparing 1-Substituted, 2-Substituted 1-H-Imidazo(4,5-c)quinolin-4-Amines IFNAR1, IRF3, IFNG SMN1; SMN2 3550/4885TSHR 3625/4885ALDH1A1 1790/4885
US-20020115861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines IFNAR1, IFNG, IRF3 SMN1; SMN2 3664/4885TSHR 3765/4885ALDH1A1 1668/4885
US-20040122231-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines UGT1A4, QARS1, HTR4 SMN1; SMN2 1806/4885TSHR 3510/4885ALDH1A1 1972/4885
US-20030119861-A1 Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines IRF3, IFNAR1, IFNG SMN1; SMN2 3585/4885TSHR 3869/4885ALDH1A1 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.